再生元制药公司宣布,其Libtayo给药方案的补充生物制品许可申请(sBLA)已在美国进入审查阶段。该申请若获批准,将为Libtayo的用药方式提供新的选择。公司方面预计,相关决定将于2027年3月出炉。
再生元制药公司宣布,其Libtayo给药方案的补充生物制品许可申请(sBLA)已在美国进入审查阶段。该申请若获批准,将为Libtayo的用药方式提供新的选择。公司方面预计,相关决定将于2027年3月出炉。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.